Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AMLX NASDAQ:PTGX NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$133.30+38.6%$111.04$7.41▼$148.83$7.67B0.693.11 million shs8.91 million shsAMLXAmylyx Pharmaceuticals$17.95-4.0%$15.14$5.97▼$19.15$2.08B-0.161.76 million shs2.44 million shsPTGXProtagonist Therapeutics$122.58+0.8%$105.08$49.38▼$126.59$7.82B1.85840,294 shs560,872 shsSYRESpyre Therapeutics$88.78-1.5%$77.15$14.00▼$102.06$7.93B3.051.77 million shs1.45 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+38.64%+35.42%+0.50%+15.94%+1,642.46%AMLXAmylyx Pharmaceuticals-4.03%+9.63%+25.06%+25.06%+179.97%PTGXProtagonist Therapeutics+0.78%+3.04%+23.12%+18.24%+121.78%SYRESpyre Therapeutics-1.53%-8.52%+20.79%+81.55%+493.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$133.30+38.6%$111.04$7.41▼$148.83$7.67B0.693.11 million shs8.91 million shsAMLXAmylyx Pharmaceuticals$17.95-4.0%$15.14$5.97▼$19.15$2.08B-0.161.76 million shs2.44 million shsPTGXProtagonist Therapeutics$122.58+0.8%$105.08$49.38▼$126.59$7.82B1.85840,294 shs560,872 shsSYRESpyre Therapeutics$88.78-1.5%$77.15$14.00▼$102.06$7.93B3.051.77 million shs1.45 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+38.64%+35.42%+0.50%+15.94%+1,642.46%AMLXAmylyx Pharmaceuticals-4.03%+9.63%+25.06%+25.06%+179.97%PTGXProtagonist Therapeutics+0.78%+3.04%+23.12%+18.24%+121.78%SYRESpyre Therapeutics-1.53%-8.52%+20.79%+81.55%+493.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.81Moderate Buy$144.468.37% UpsideAMLXAmylyx Pharmaceuticals 2.90Moderate Buy$24.2535.13% UpsidePTGXProtagonist Therapeutics 2.88Moderate Buy$115.21-6.01% DownsideSYRESpyre Therapeutics 3.00Buy$95.837.94% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, PTGX, ABVX, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026ABVXAbivax HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/30/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$150.00 ➝ $175.006/30/2026ABVXAbivax Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$108.00 ➝ $158.006/30/2026ABVXAbivax Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$140.00 ➝ $148.006/30/2026ABVXAbivax WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$90.00 ➝ $110.006/25/2026AMLXAmylyx Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $40.006/23/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $135.006/16/2026SYRESpyre Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$100.006/16/2026ABVXAbivax BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.006/15/2026SYRESpyre Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $112.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AAMLXAmylyx Pharmaceuticals$87.37M22.84N/AN/A$2.78 per share6.46PTGXProtagonist Therapeutics$46.02M171.30N/AN/A$9.83 per share12.47SYRESpyre Therapeutics$890K8,772.26N/AN/A$7.21 per share12.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.21N/AN/AN/AN/A-99.02%-70.26%9/14/2026 (Estimated)AMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest AMLX, PTGX, ABVX, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2026Q1 2026ABVXAbivax-$0.9359-$0.71+$0.2259-$0.71$0.40 million$1.56 million5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.258.25AMLXAmylyx PharmaceuticalsN/A17.8517.85PTGXProtagonist TherapeuticsN/A17.7617.76SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AMLXAmylyx Pharmaceuticals95.84%PTGXProtagonist Therapeutics98.63%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAMLXAmylyx Pharmaceuticals10.90%PTGXProtagonist Therapeutics5.19%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.77 millionN/ANot OptionableAMLXAmylyx Pharmaceuticals200111.19 million99.07 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableSYRESpyre Therapeutics7387.94 million73.22 millionOptionableAMLX, PTGX, ABVX, and SYRE HeadlinesRecent News About These CompaniesSpyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting DataJune 30 at 7:32 PM | seekingalpha.comIs SYRE Stock a Buy Now or a Wait-and-See Biotech Story TodayJune 29 at 12:25 PM | zacks.comSpyre Therapeutics Stock Outlook Hinges on 2026 Study CatalystsJune 29 at 12:21 PM | zacks.comSYRE and Spyre Ride New IBD Trends in Biotech Drug DesignJune 29 at 12:21 PM | zacks.comScott Burrows Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 28 at 4:37 AM | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,306,950.00 in StockJune 27, 2026 | insidertrades.comBiotech ETF Index Surges 10% After RebalanceJune 25, 2026 | etftrends.comESpyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High After Analyst UpgradeJune 25, 2026 | americanbankingnews.comSpyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)June 24, 2026 | finance.yahoo.comMichael Thomas Henderson Sells 20,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 24, 2026 | insidertrades.comStifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)June 23, 2026 | theglobeandmail.comSpyre Therapeutics Inc SYREJune 18, 2026 | morningstar.comMAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)June 18, 2026 | theglobeandmail.comSpyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term StudyJune 18, 2026 | tipranks.comPerceptive Advisors LLC Buys 1,839,780 Shares of Spyre Therapeutics, Inc. $SYREJune 18, 2026 | marketbeat.comSpyre Therapeutics, Inc. $SYRE Stock Position Boosted by Commodore Capital LPJune 18, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)June 16, 2026 | theglobeandmail.comSpyre Expands SPY003 Rights Beyond Inflammatory Bowel DiseaseJune 16, 2026 | theglobeandmail.comSpyre says bowel disease drug cuts inflammation in mid-stage trialJune 15, 2026 | reuters.comSpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsJune 15, 2026 | globenewswire.comHealthcare ETFs: From Broad Exposure to Big BreakthroughsJune 11, 2026 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeAMLX, PTGX, ABVX, and SYRE Company DescriptionsAbivax NASDAQ:ABVX$133.30 +37.15 (+38.64%) Closing price 06/30/2026 03:59 PM EasternExtended Trading$133.15 -0.15 (-0.11%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Amylyx Pharmaceuticals NASDAQ:AMLX$17.95 -0.75 (-4.03%) Closing price 06/30/2026 03:59 PM EasternExtended Trading$17.88 -0.07 (-0.39%) As of 06:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$122.58 +0.95 (+0.78%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$123.08 +0.50 (+0.41%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Spyre Therapeutics NASDAQ:SYRE$88.78 -1.38 (-1.53%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$88.00 -0.78 (-0.88%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
